Zydus Lifesciences Ltd.

“Zydus Lifesciences is a credible mid-tier Indian pharma company with improving margins, a clean balance sheet, and a genuine reinvestment runway in US complex generics and India chronic-care — but it trades at fair value with minimal margin of safety (~7% upside to DCF), requires ~13% EPS CAGR to justify the current price, and carries endemic sector risks (FDA compliance, US generic erosion, M&A execution) that collectively warrant a meaningful discount before initiating a position; the business deserves a watchlist slot and a target entry near ₹800–830.”